Literature DB >> 29142087

No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.

Marco Pisa1, Simone Guerrieri1, Giovanni Di Maggio1, Stefania Medaglini1, Lucia Moiola1, Vittorio Martinelli1, Giancarlo Comi1, Letizia Leocani2.   

Abstract

OBJECTIVE: To explore, in a longitudinal study, the usefulness of optical coherence tomography (OCT) in monitoring people with multiple sclerosis (MS) by testing the association between retinal nerve fiber layer (RNFL) thinning and clinical and brain MRI criteria of no evidence of disease activity (NEDA).
METHODS: OCT, visual evoked potentials (VEPs), and disability, using the Expanded Disability Status Scale (EDSS), were tested at baseline and after 2 years in 72 patients, 63 with routine yearly brain MRI.
RESULTS: Longitudinal mean binocular RNFL thinning, in absence of optic neuritis during follow-up, was correlated with EDSS worsening, also controlling for baseline EDSS, RNFL, disease duration, and MS subtype (Spearman ρ -0.462, p < 0.001; partial correlation coefficient -0.437, p < 0.001). At follow-up, patients classified as NEDA (20; 31.7%) had RNFL loss of -0.93 μm ± 1.35 SD, while patients with active disease had -2.83 μm ± 2 SD thinning (t test; p < 0.001). At logistic regression, mean RNFL reduction correctly classified 76.2% of patients as NEDA at 2 years (R2 0.355; p = 0.003). A cutoff of -1.25 μm RNFL loss classified NEDA status with specificity 81.4% and sensitivity 80% (receiver operating characteristic curve: area under the curve 0.8; p < 0.001). No significant longitudinal correlations were found between changes in RNFL and in VEP latencies or scores.
CONCLUSIONS: NEDA is associated with a relatively preserved RNFL over 2 years. A greater neuroretinal loss was detected even in patients with clinical evidence of disease activity independently from changes in brain MRI lesions, prompting further validation of OCT as an additional tool in MS monitoring.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 29142087     DOI: 10.1212/WNL.0000000000004736

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study.

Authors:  Anna M Pietroboni; Tiziana Carandini; Laura Dell'Arti; Francesca Bovis; Annalisa Colombi; Milena A De Riz; Elena Casazza; Elisa Scola; Chiara Fenoglio; Andrea Arighi; Giorgio G Fumagalli; Fabio Triulzi; Daniela Galimberti; Francesco Viola; Elio Scarpini
Journal:  Neurol Sci       Date:  2020-04-30       Impact factor: 3.307

Review 2.  Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials.

Authors:  Elizabeth Silbermann; Lindsey Wooliscroft; Dennis Bourdette
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-19       Impact factor: 5.081

3.  Multifocal visual evoked potentials and contrast sensitivity correlate with ganglion cell-inner plexiform layer thickness in multiple sclerosis.

Authors:  Divya Narayanan; Han Cheng; Rosa A Tang; Laura J Frishman
Journal:  Clin Neurophysiol       Date:  2018-11-13       Impact factor: 3.708

4.  Retinal Nerve Fiber Layer Thickness Correlates with Serum and Cerebrospinal Fluid Neurofilament Levels and is Associated with Current Disability in Multiple Sclerosis.

Authors:  Cihat Uzunköprü; Nur Yüceyar; Suzan Güven Yilmaz; Filiz Afrashi; Özgül Ekmekçi; Dilek Taşkiran
Journal:  Noro Psikiyatr Ars       Date:  2021-01-16       Impact factor: 1.339

5.  Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease.

Authors:  Cláudia Y Santos; Lenworth N Johnson; Stuart E Sinoff; Elena K Festa; William C Heindel; Peter J Snyder
Journal:  Alzheimers Dement (Amst)       Date:  2018-02-07

Review 6.  Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?

Authors:  Fiona Costello; Jodie M Burton
Journal:  Eye Brain       Date:  2018-07-31

7.  The Role of Optical Coherence Tomography in Differential Diagnosis of Multiple Sclerosis and Autoimmune Connective Tissue Diseases with CNS Involvement.

Authors:  Paula Wildner; Ewa Zydorczak; Magdalena Oset; Małgorzata Siger; Michał Wilczyński; Mariusz Stasiołek; Mariola Matysiak
Journal:  J Clin Med       Date:  2020-05-21       Impact factor: 4.241

8.  Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study.

Authors:  Eleonora Tavazzi; Dejan Jakimovski; Jens Kuhle; Jesper Hagemeier; Osman Ozel; Murali Ramanathan; Christian Barro; Niels Bergsland; Davorka Tomic; Harald Kropshofer; David Leppert; Zuzanna Michalak; Norah Lincoff; Michael G Dwyer; Ralph H B Benedict; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-05-18

9.  Functional and structural changes in the visual pathway in multiple sclerosis.

Authors:  María Carcelén-Gadea; Carlos Quintanilla-Bordás; Alicia Gracia-García; Carolina García-Villanueva; Nicolás Jannone-Pedro; Lourdes Álvarez-Sánchez; Laura Vilaplana-Domínguez; Trinidad Blanco-Hernández; José Miguel Pons-Amate; Angeles Cervelló-Donderis
Journal:  Brain Behav       Date:  2019-11-16       Impact factor: 2.708

Review 10.  Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.

Authors:  Jeroen Van Schependom; Kaat Guldolf; Marie Béatrice D'hooghe; Guy Nagels; Miguel D'haeseleer
Journal:  Transl Neurodegener       Date:  2019-12-09       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.